Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

2articles mentioning drugs

10drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: SynKIR-110 ×

SynKIR-110

This drug is selected. Its supporting articles are shown below.

SynKIR-1102

Articles mentioning SynKIR-110

2 articles · page 1 of 1

298 A novel NK-cell based split-signaling killer immunoglobulin receptor (KIR)-based CAR T targeting mesothelin, SynKIR-110, shows increased safety profile and increased efficacy in vitro and in vivo

jitc · abstract · 2025-11-04 · 9 matching annotations

97.8%

SynKIR-110 SS1-41BBz SS1-41BBζ solid tumors SAE

…ells, both in vitro and in vivo. These results findings support SynKIR-110 as a promising candidate with improved safety and efficacy for …

1238 Histopathologic analysis of mesothelin expression in cholangiocarcinoma supports inclusion in biomarker-targeted clinical trials

jitc · abstract · 2025-11-04 · 1 matching annotations

87.3%

SynKIR-110 University of Pennsylvania cholangiocarcinoma immunotherapy chemotherapy CCA ovarian carcinomas surgery radiation ovarian cancer+2 more

…tive tumor MSLN testing for potential correlates with outcomes. SynKIR-110 is a MSLN-targeted KIR-CAR T cell therapy in a Phase 1 clinical…